In a first, US approves AstraZeneca antibody for cases reacting badly to vaccine

FacebookTwitterWhatsAppCopy Link

Washington: US health authorities has approved the use of synthetic antibodies developed by AstraZeneca to prevent Covid-19 infections in people who react badly to vaccines.

It was the first time the Food and Drug Administration has given emergency authorization for such a purely preventative treatment.

The FDA warned the drug Evusheld is “not a substitute for vaccination in individuals for whom Covid-19 vaccination is recommended” and can only be authorized for people who have a weakened immune system or those who cannot be vaccinated for medical reasons, such a strong allergic reaction.

In those cases, the drug can be administered to people aged 12 and up.